Khiron Life Sciences Director and Former President of Mexico, Mr. Vicente Fox to Present Keynote Address at Global Cannabis Business Conference in Jamaica

Wednesday, September 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Conference to offer insight on global medicinal, health, regulatory, business and investment landscape

TORONTO, Sept.

26, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN, OTCQB: KHRNF, Frankfurt: A2JMZC), a Canadian integrated medical cannabis company with its core operations in Colombia,
announced that former President of Mexico and Khiron Board member Mr. Vicente Fox will present a keynote address at CanEx Jamaica Business Conference & Expo on September 28th in Montego Bay, Jamaica, where he will discuss his views on the medical cannabis industry in Mexico and Latin America.

Mr. Fox stated, "The cannabis industry offers tremendous economic health and social benefits in Mexico and around the world. I welcome the opportunity to share, network and advocate for its continued progress at CanEx Jamaica." From December 2000 to November 2006, Mr. Fox was the 55th President of Mexico. Prior to that, he was the Chief Executive Officer of Coca Cola Latin America.

Mr. Alvaro Torres, Khiron Co-founder and CEO stated: "We congratulate Mr. Fox on this invitation to present at CanEx Jamaica. As an important global cannabis conference his active participation articulates and reinforces Khiron´s vision of becoming the leading medical cannabis company across Latin America."

The CanEx Jamaica Business Conference and Expo is an annual business-to-business event that brings together top cannabis industry experts from the U.S., Canada, South and Central America, Europe, Australia and the Caribbean. For further detail visit www.canexjamaica.com

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp.  (TSXV: KHRN, OTCQB: KHRNF, Frankfurt: A2JMZC)) ("Khiron" or the "Company") is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. 

Further information on Khiron Life Sciences can be found at www.khiron.ca.

Forward-Looking Statements

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Filing Statement which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store